Completed PHASE3 INTERVENTIONAL 2-arm NCT01462890

Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST)

A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Sponsor: AGO Study Group

Conditions Fallopian Tube Neoplasms Genital Diseases, Female Ovarian Diseases Ovarian Neoplasms Peritoneal Neoplasms

Interventions Bevacizumab Carboplatin Paclitaxel specialized pathology review (Germany only)

Updated 10 times since 2017 Last updated: Jul 19, 2022 Started: Nov 30, 2011 Primary completion: Dec 31, 2020 Completion: Dec 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Fallopian Tube Neoplasms and Genital Diseases, Female and is currently completed. AGO Study Group leads this study, which shows 10 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2022 — Jul 2024 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Feb 2021 — Sep 2022 [monthly]

Active Not Recruiting PHASE3

▶ Show 5 earlier versions

Jan 2021 — Feb 2021 [monthly]

Active Not Recruiting PHASE3
Aug 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Aug 2020 [monthly]

Active Not Recruiting PHASE3
Aug 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Aug 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AGO Study Group
ARCAGY/ GINECO GROUP
Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Data source: AGO Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Aalborg, Denmark , Angers, France , Arnsberg, Germany , Aschaffenburg, Germany , Augsburg, Germany , Bad Homburg, Germany , Bergen, Norway , Berlin, Germany , Besançon, France and 121 more locations